ASXC

false 0000876378 0000876378 2022-05-10 2022-05-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

 

FORM 8-K

_________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

May 10, 2022
Date of Report (date of earliest event reported)

_________________

 

Asensus Surgical, Inc.

(Exact name of Registrant as specified in its charter)

_________________

 

1 TW Alexander Drive, Suite 160

Durham, NC 27703
(Address of principal executive offices)

919-765-8400
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

_________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐  

 

 

Item 8.01 Other Events

 

As previously reported by Asensus Surgical, Inc. (the “Company”), the Company has entered into a Controlled Equity Offering^SM Sales Agreement with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., dated May 19, 2021 and amended on March 18, 2022 (the “Agreement”), for the sale of up to $100,000,000 in shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in an “at the market offering” pursuant to the Agreement. On May 10, 2022, the Company filed a prospectus supplement relating to the “at the market offering” of such shares of Common Stock under the Agreement. Such shares of Common Stock are registered under the Registration Statement on Form S-3 (File No. 333-263711) filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended, and declared effective on April 28, 2022.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

 

* Filed herewith.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.